TRIM16L

Across TCGA pan-cancer cohorts, TRIM16L Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRIM16L data layer compared with 21 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TRIM16L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRIM16L expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, CESC, and SKCM are the cancer types where TRIM16L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.142	0.707	<.001	18	view →
CESC	DFS	Median	All	0.460	0.826	.008	10	view →
SKCM	OS	Median	All	0.538	0.789	.019	8	view →
HNSC	OS	Median	IV	0.013	0.733	<.001	6	view →
UCEC	DFS	Median	II,III,IV	1.000	0.488	.045	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRIM16L–LIHC (OS)

Open the LIHC breakdown →